Strategies to Extend Thrombolytic Time Window for Ischemic Stroke Treatment: An Unmet Clinical Need
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
To date, reperfusion with tissue plasminogen activator (tPA) remains the gold standard treatment for ischemic stroke. However, when tPA is given beyond 4.5 hours of stroke onset, deleterious effects of the drug ensue, especially, hemorrhagic transformation (HT), which causes the most significant morbidity and mortality in stroke patients. An important clinical problem at hand is to develop strategies that will enhance the therapeutic time window for tPA therapy and reduce the adverse effects (especially HT) of delayed tPA treatment. We reviewed the pharmacological agents which reduced the risk of HT associated with delayed (beyond 4.5 hours post-stroke) tPA treatment in preclinical studies, which we classified into those that putatively preserve the blood-brain barrier (e.g., minocycline, cilostazol, fasudil, candesartan, and bryostatin) and/or enhance vascularization and protect the cerebrovasculature (e.g., coumarin derivate IMM-H004 and granulocyte colony-stimulating factor). Recently, other new therapeutic modalities (e.g., oxygen transporters) have been reported which improved delayed tPA-associated outcomes by acting through other mechanisms. While the above-mentioned interventions unequivocally reduced delayed tPA-induced HT in stroke models, the long-term efficacy of these drugs are not yet established. Further optimization is required to expedite their future clinical application. The findings from this review indicate the need to explore the most ideal adjunctive interventions that will not only reduce delayed tPA–induced HT, but also preserve neurovascular functions. While waiting for the next breakthrough drug in acute stroke treatment, it is equally important to allocate considerable effort to find approaches to address the limitations of the only FDA-approved stroke therapy.
Abstract
To date, reperfusion with tissue plasminogen activator (tPA) remains the gold standard treatment for ischemic stroke. However, when tPA is given beyond 4.5 hours of stroke onset, deleterious effects of the drug ensue, especially, hemorrhagic transformation (HT), which causes the most significant morbidity and mortality in stroke patients. An important clinical problem at hand is to develop strategies that will enhance the therapeutic time window for tPA therapy and reduce the adverse effects (especially HT) of delayed tPA treatment. We reviewed the pharmacological agents which reduced the risk of HT associated with delayed (beyond 4.5 hours post-stroke) tPA treatment in preclinical studies, which we classified into those that putatively preserve the blood-brain barrier (e.g., minocycline, cilostazol, fasudil, candesartan, and bryostatin) and/or enhance vascularization and protect the cerebrovasculature (e.g., coumarin derivate IMM-H004 and granulocyte colony-stimulating factor). Recently, other new therapeutic modalities (e.g., oxygen transporters) have been reported which improved delayed tPA-associated outcomes by acting through other mechanisms. While the above-mentioned interventions unequivocally reduced delayed tPA-induced HT in stroke models, the long-term efficacy of these drugs are not yet established. Further optimization is required to expedite their future clinical application. The findings from this review indicate the need to explore the most ideal adjunctive interventions that will not only reduce delayed tPA–induced HT, but also preserve neurovascular functions. While waiting for the next breakthrough drug in acute stroke treatment, it is equally important to allocate considerable effort to find approaches to address the limitations of the only FDA-approved stroke therapy.
참고문헌 (61)
- Albers GW, "Expanding the window for thrombolytic therapy in acute stroke. The potential role of acute MRI for patient selection", Stroke, 30, pp.2230~2237 (1999)
- Hacke W, "Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke", N Engl J Med, 359, pp.1317~1329 (2008)
- Go AS, "Heart disease and stroke statistics—2014 update: a report from the American Heart Association", Circulation, 129, pp.e28~e292 (2014)
- NINDS rt-PA Stroke Study Group, "Intracerebral hemorrhage after intravenous tPA therapy for ischemic stroke", Stroke, 28, pp.2109~2118 (1997)
- Greenberg DA, "Neurogenesis and stroke", CNS Neurol Disord Drug Targets, 6, pp.321~325 (2007)
- Adams HP Jr, "Guidelines for the early management of patients with ischemic stroke: a scientific statement from the Stroke Council of the American Stroke Association", Stroke, 34, pp.1056~1083 (2003)
- Wang X, "Mechanisms of hemorrhagic transformation after tissue plasminogen activator reperfusion therapy for ischemic stroke", Stroke, 35, pp.2726~2730 (2004)
- Wang W, "Hemorrhagic transformation after tissue plasminogen activator reperfusion therapy for ischemic stroke: mechanisms, models, and biomarkers", Mol Neurobiol, 52, pp.1572~ (2015)
- Jickling GC, "Hemorrhagic transformation after ischemic stroke in animals and humans", J Cereb Blood Flow Metab, 34, pp.185~199 (2014)
- Lapchak PA, "Hemorrhagic transformation following ischemic stroke: significance, causes, and relationship to therapy and treatment", Curr Neurol Neurosci Rep, 2, pp.38~43 (2002)
- Won S, "Progesterone attenuates hemorrhagic transformation after delayed tPA treatment in an experimental model of stroke in rats: involvement of the VEGF-MMP pathway", J Cereb Blood Flow Metab, 34, pp.72~80 (2014)
- Ballabh P, "The blood–brain barrier: an overview: structure, regulation, and clinical implications", Neurobiol Dis, 16, pp.1~13 (2004)
- Ishiguro M, "A Rho kinase (ROCK) inhibitor, fasudil, prevents matrix metalloproteinase-9-related hemorrhagic transformation in mice treated with tissue plasminogen activator", Neuroscience, 220, pp.302~312 (2012)
- Ishiguro M, "Phosphodiesterase-III inhibitor prevents hemorrhagic transformation induced by focal cerebral ischemia in mice treated with tPA", PLoS One, 5, pp.e15178~ (2010)
- Machado LS, "Delayed minocycline inhibits ischemia-activated matrix metalloproteinases 2 and 9 after experimental stroke", BMC Neurosci, 7, pp.56~ (2006)
- Murata Y, "Extension of the thrombolytic time window with minocycline in experimental stroke", Stroke, 39, pp.3372~3377 (2008)
- Fagan SC, "Minocycline to improve neurologic outcome in stroke (MINOS): a dose-finding study", Stroke, 41, pp.2283~2287 (2010)
- Switzer JA, "Matrix metalloproteinase-9 in an exploratory trial of intravenous minocycline for acute ischemic stroke", Stroke, 42, pp.2633~2635 (2011)
- Blacker DJ, "Reducing haemorrhagic transformation after thrombolysis for stroke: a strategy utilising minocycline", Stroke Res Treat, 2013, pp.362961~ (2013)
- Matsumoto M, "Cilostazol in secondary prevention of stroke: impact of the cilostazol stroke prevention study", Atheroscler Suppl, 6, pp.33~40 (2005)
- Koto T, "Hypoxia disrupts the barrier function of neural blood vessels through changes in the expression of claudin-5 in endothelial cells", Am J Pathol, 170, pp.1389~1397 (2007)
- Hao JL, "Galardin inhibits collagen degradation by rabbit keratocytes by inhibiting the activation of pro-matrix metalloproteinases", Exp Eye Res, 68, pp.565~572 (1999)
- Mishiro K, "A broad-spectrum matrix metalloproteinase inhibitor prevents hemorrhagic complications induced by tissue plasminogen activator in mice", Neuroscience, 205, pp.39~48 (2012)
- Mayne M, "Antisense oligodeoxynucleotide inhibition of tumor necrosis factor-alpha expression is neuroprotective after intracerebral hemorrhage", Stroke, 32, pp.240~248 (2001)
- Shibuya M, "Effect of AT877 on cerebral vasospasm after aneurismal subarachnoid hemorrhage", J Neurosurg, 76, pp.571~577 (1992)
- Fu H, "Therapeutic effects of postischemic treatment with hypotensive doses of an angiotensin II receptor blocker on transient focal cerebral ischemia", J Hypertens, 29, pp.2210~2219 (2011)
- Ishrat T, "Candesartan reduces the hemorrhage associated with delayed tissue plasminogen activator treatment in rat embolic stroke", Neurochem Res, 38, pp.2668~2677 (2013)
- Suzuki Y, "Stromelysin-1 (MMP-3) is critical for intracranial bleeding after t-PA treatment of stroke in mice", J Thromb Haemost, 5, pp.1732~1739 (2007)
- Huang Z, "Enlarged infarcts in endothelial nitric oxide synthase knockout mice are attenuated by nitro-L-arginine", J Cereb Blood Flow Metab, 16, pp.981~987 (1996)
- Tan Z, "Bryostatin improves survival and reduces ischemic brain injury in aged rats after acute ischemic stroke", Stroke, 44, pp.3490~3497 (2013)
- Tan Z, "Bryostatin extends tPA time window to 6 h following middle cerebral artery occlusion in aged female rats", Eur J Pharmacol, 764, pp.404~412 (2015)
- Ding Q, "Matrix metalloproteinases modulated by protein kinase Cepsilon mediate resistin-induced migration of human coronary artery smooth muscle cells", J Vasc Surg, 53, pp.1044~1051 (2011)
- Keep RF, "Vascular disruption and blood-brain barrier dysfunction in intracerebral hemorrhage", Fluids Barriers CNS, 11, pp.18~ (2014)
- Meenakshisundaram T, "Activated protein C promotes neovascularization and neuro-genesis in post-ischemic brain via protease activated receptor 1", J Neurosci, 28, pp.12788~12797 (2008)
- Fylaktakidou KC, "Natural and synthetic coumarin deriv58atives with anti-inflammatory", antioxidant activities, 2004, pp.30, 3813~3833
- Zuo W, "IMM-H004 prevents toxicity induced by delayed treatment of tPA in a rat model of focal cerebral ischemia involving PKA-and PI3K-dependent Akt activation", Eur J Neurosci, 39, pp.2107~2118 (2014)
- Hartung T, "Anti-inflammatory effects of granulocyte colony-stimulating factor", Curr Opin Hematol, 5, pp.221~225 (1998)
- dela Peña IC, "Granulocyte colony-stimulating factor attenuates delayed tPA-induced hemorrhagic transformation in ischemic stroke rats by enhancing angiogenesis and vasculogenesis", J Cereb Blood Flow Metab, 35, pp.338~346 (2015)
- Sobrino T, "Association of growth factors with arterial recanalization and clinical outcome in patients with ischemic stroke treated with tPA", J Thromb Haemost, 8, pp.1567~1574 (2010)
- Ullegaddi R, "Antioxidant supplementation with or without B-group vitamins after acute ischemic stroke: a randomized controlled trial", JPEN J Parenter Enteral Nutr, 30, pp.108~114 (2006)
- Allahtavakoli M, "Ascorbic acid reduces the adverse effects of delayed administration of tissue plasminogen activator in a rat stroke model", Basic Clin Pharmacol Toxicol, 117, pp.335~339 (2015)
- Culp WC, "Dodecafluoropentane emulsion extends window for tPA therapy in a rabbit stroke model", Mol Neurobiol, 52, pp.979~984 (2015)
- Albers GW, "Stroke Treatment Academic Industry Roundtable (STAIR) recommendations for maximizing the use of intravenous thrombolytics and expanding treatment options with intra-arterial and neuroprotective therapies", Stroke, 42, pp.2645~2650 (2011)
- Lapchak PA, "RIGOR guidelines: escalating STAIR and STEPS for effective translational research", Transl Stroke Res, 4, pp.279~285 (2013)
- Korninger C, "Studies on the specific fibrinolytic effect of human extrinsic (tissue-type) plasminogen activator in human blood and in various animal species in vitro", Thromb Haemost, 46, pp.561~565 (1981)
- Haelewyn B, "Human recombinant tissue-plasminogen activator (alteplase): why not use the ‘human’ dose for stroke studies in rats?", J Cereb Blood Flow Metab, 30, pp.900~903 (2010)
- Jiang Y, "Low dose tPA plus annexin A2 combination attenuates tPA delayed treatment-associated hemorrhage and improves recovery in rat embolic focal stroke", Neurosci Lett, 602, pp.73~78 (2015)
- Zhu H, "Annexin A2 combined with low-dose tPA improves thrombolytic therapy in a rat model of focal embolic stroke", J Cereb Blood Flow Metab, 30, pp.1137~1146 (2010)
- Borlongan CV, "Bone marrow stem cell mobilization in stroke: a ‘bonehead’ may be good after all!", Leukemia, 25, pp.1674~1686 (2011)
- dela Peña I, "Neural Stem Cells in Health and Disease", pp.371~408 (2015), World Scientific Publishing Co.
- Bentley P, "Prediction of stroke thrombolysis outcome using CT brain machine learning", Neuroimage Clin, 4, pp.635~640 (2014)
- Berkhemer OA, "A randomized trial of intraarterial treatment for acute ischemic stroke", N Engl J Med, 372, pp.1009~1018 (2014)
- Minnerup J, "Outcome after thrombectomy and intravenous thrombolysis in patients with acute ischemic stroke: a prospective observational study", Stroke, 47, pp.1584~1592 (2016)
- Rubin MN, "What to do with wake-up stroke", Neurohospitalist, 5, pp.161~172 (2015)
- Whiteley WN, "Risk of intracerebral haemorrhage with alteplase after acute ischaemic stroke: a secondary analysis of an individual patient data meta-analysis", Lancet Neurol, 15, pp.925~933 (2016)
- Amaro S, "Uric acid therapy prevents early ischemic stroke progression: a tertiary analysis of the URICO-ICTUS trial (efficacy study of combined treatment with uric acid and r-tPA in acute ischemic stroke)", Stroke, 47, pp.2874~2876 (2016)
- Toni D, "Progressing neurological deficit secondary to acute ischemic stroke. A study on predictability, pathogenesis, and prognosis", Arch Neurol, 52, pp.670~675 (1995)
- Parsons M, "A randomized trial of tenecteplase versus alteplase for acute ischemic stroke", N Engl J Med, 366, pp.1099~1107 (2012)
- Henninger N, "Extending the time window for endovascular and pharmacological reperfusion", Transl Stroke Res, 7, pp.284~293 (2016)
- Ehrenreich H, "Recombinant human erythropoietin in the treatment of acute ischemic stroke", Stroke, 40, pp.e647~e656 (2009)
- Ishrat T, "Vascular protection to increase the safety of tissue plasminogen activator for stroke", Curr Pharm Des, 18, pp.3677~3684 (2012)